The Premier Consulting Blog

JULY 9, 2023

During the development of new small molecule drug products, developers must conduct impurity and degradant evaluation at several points in the program and to varying degrees. These evaluations include the active pharmaceutical ingredient (API), also known as the drug substance, and the drug product (formulated product).

Small Molecule 52

Small Molecule DNA Drugs Clinical Development 52

The Pharma Data

DECEMBER 10, 2020

11, 2020 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. Food and Drug Administration (FDA) for the development of LX9211 in diabetic peripheral neuropathic pain. executive vice president of research and development. “The executive vice president of research and development. “We About Lexicon Pharmaceuticals.

FDA 52

FDA Pharmaceuticals Small Molecule Clinical Development 52

Drug Target Review

JULY 18, 2023

AI is being used to find the targets themselves, design the drugs to manipulate that biology, and thirdly, AI is being used to support validation of those targets and drugs as part of pre-clinical development. With support from pharmaceutical companies, ultimately, the answer to this question should be yes.

Drug Development 98

Drug Development Drugs Clinical Development Pharmaceutical Companies 98

The Pharma Data

OCTOBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Eloxx Pharmaceuticals, Inc. About Eloxx Pharmaceuticals. Eloxx Pharmaceuticals, Inc. Eloxx’s lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. SOURCE: Eloxx Pharmaceuticals, Inc.

Pharmaceuticals 52

Pharmaceuticals RNA Small Molecule Protein Production 52

The Pharma Data

OCTOBER 26, 2020

27, 2020 /PRNewswire/ — Aridis Pharmaceuticals, Inc. Dr. Hasan Jafri , Chief Medical Officer of Aridis Pharmaceuticals, will be a speaker on a panel entitled “Direct Antivirals and Other Agents Against SARS-CoV2 Virus.” About Aridis Pharmaceuticals, Inc. Aridis Pharmaceuticals, Inc. SAN JOSE, Calif. ,

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

The Pharma Data

MARCH 28, 2022

For more than a decade Sanofi, in collaboration with Regeneron Pharmaceuticals, Inc. Two complementary candidates for COPD , developed in collaboration with Regeneron, targeting distinct subpopulations. A broad Phase 1 clinical program of small molecules and biologics.

Small Molecule 52

Small Molecule Clinical Development Disease Science 52

The Pharma Data

JANUARY 13, 2021

14, 2021 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals, Inc. Tonix Pharmaceuticals Holding Corp. Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering.

Pharmaceuticals 52

Pharmaceuticals Small Molecule Vaccine Protein Expression 52

The Pharma Data

JUNE 28, 2021

Broadens company’s oncology platform of Targeted Alpha Therapies / Acquisition includes actinium-225 labeled differentiated PSMA small molecule for the treatment of prostate cancer. Xofigo is currently under further evaluation in a broad clinical development program in prostate cancer and beyond.

Small Molecule 52

Small Molecule Licensing Licensing Therapies 52

The Pharma Data

OCTOBER 18, 2020

Dr. Berk, commented “I am excited to join the Board of Inflection Biosciences as it advances its novel PIM/PI3K inhibitor, IBL-202, towards clinical development for unmet needs in B-cell malignancies and other cancers.”. Dr. Berk most recently has served as a consultant to several companies developing oncology therapies.

Small Molecule 40

Small Molecule Clinical Development Clinical Trials Licensing 40

The Pharma Data

FEBRUARY 22, 2021

Eli Lilly and Company (NYSE: LLY) and Rigel Pharmaceuticals, Inc. Pursuant to the collaboration, Lilly will also lead all clinical development of brain penetrating RIPK1 inhibitors in central nervous system (CNS) diseases. Rigel also has ongoing pre-clinical activities with its lead CNS penetrant RIPK1 inhibitor candidates.

Clinical Development 40

Clinical Development Small Molecule Clinical Trials Immune Response 40

The Pharma Data

OCTOBER 14, 2020

. Potential Development of Human Monoclonal Antibody Therapeutics to SARS-CoV-2. 15, 2020 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. President and Chief Executive Officer of Tonix Pharmaceuticals. About Tonix Pharmaceuticals Holding Corp. CHATHAM, N.J., 1 Noyce RS, et al.

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

The Pharma Data

DECEMBER 17, 2020

Hartfield previously served as CEO of Vitae Pharmaceuticals prior to its acquisition by Allergan. X4 Pharmaceuticals – Diego Cadavid was named chief medical officer of Boston-based X4 Pharmaceuticals. Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs.

Small Molecule 52

Small Molecule Engineering Clinical Development Pharmaceuticals 52

The Pharma Data

FEBRUARY 21, 2022

At its annual Pharma Media Day 2022, Bayer presented the latest developments in the ongoing transformation of its pharmaceuticals business, which is aimed at delivering long-term, sustainable business growth by bringing forward new options for patients. “We

Clinical Trials 52

Clinical Trials Small Molecule Clinical Development Disease 52

The Pharma Data

DECEMBER 21, 2020

Program focused on identifying small molecules that target a GPCR for degradation as potential therapeutic agents for gastrointestinal disorders. The principle of TPD is to use small molecules to commit the target protein into the E3 ligase-mediated degradation pathway thereby eliminating or reducing its activity.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Structure Based Drug Design (SBDD) Drugs 40

The Pharma Data

NOVEMBER 23, 2020

At Ultimovacs, he will lead all business and corporate development efforts and continue to maintain and foster connections with leading biotechnology and pharmaceutical companies. “In

Clinical Trials 52

Clinical Trials Small Molecule Pharmaceutical Companies Licensing 52

Drug Target Review

JULY 11, 2023

Spending a couple of years practicing on the wards around London, and then moving into management consulting at McKinsey & Company which led her to work in pharmaceutical research and development (R&D). She also co-founded and sits on the Board of Directors of Sevenless Therapeutics, a small molecule pain company.

Disease 75

Disease RNA Small Molecule Clinical Development 75

Agency IQ

JUNE 9, 2023

For this reason, animal models are still used both during drug discovery and the more intensive nonclinical studies conducted during clinical development. However, this guideline is primarily intended to provide recommendations on evaluating the immune system’s response to small molecule drugs.

FDA 40

FDA Small Molecule Science Immune Response 40

Precision for Medicine

JUNE 26, 2023

“Our partnerships are with the most innovative organizations, utilizing the most advanced, cutting-edge technologies and providing us with unparalleled experience in manufacturing small molecule, biologics and next-generation medicines,” said John Khoury, Executive Vice President at Project Farma.

Science 40

Science Small Molecule Clinical Research Engineering 40

LifeSciVC

APRIL 27, 2023

Fourteen years on, this corporate experiment has gone far beyond the initial idea, and has established an R&D engine more effective than most big pharma R&D groups at producing best-in-class small molecules against targets that matter in human disease biology. Our long-time clinical development lead, Bhaskar Srivastava, an M.D.

Small Molecule 52

Small Molecule Computational Chemistry Engineering Clinical Development 52

The Pharma Data

JUNE 26, 2021

As part of its development strategy, BioNTech aims to rapidly advance its broad oncology pipeline and expects to bring additional candidates into late-stage clinical development and towards market entry within the next five years. About FixVac. Source link: [link].

Clinical Trials 52

Clinical Trials Trials Immune Response Vaccine 52

The Pharma Data

NOVEMBER 5, 2020

X4 Pharmaceuticals – Art Taveras was named CSO of Cambridge, Mass.-based Taveras will lead all research and non-clinical development functions supporting the company’s pipeline of investigational therapies. Venugopal most recently served as executive director at Intercept Pharmaceuticals.

Analytical Chemistry 40

Analytical Chemistry Pharmaceuticals Small Molecule Therapies 40

The Pharma Data

OCTOBER 19, 2020

The appointments of Maarten and Teun come at an essential time for AM-Pharma as we finalize all preparations to move into the last stage of clinical development for our lead program,” said Erik van den Berg , Chief Executive Officer at AM-Pharma. Dr. Kraan joins AM-Pharma from Pierre Fabre S.A., Kenilworth, N.J.,

Trials 40

Trials Small Molecule Cell Biology Clinical Trials 40

The Pharma Data

JANUARY 19, 2021

TC-210 is currently in a Phase I/II trial for mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Syros Pharmaceuticals – Syros announced its IPO on January 20, offering 5.4 million shares of common stock at $14 per share, to raise $75.6

Small Molecule 52

Small Molecule Trials Laboratories Immune Response 52

Codon

MARCH 20, 2023

Marine biofilm engineered to produce current in response to small molecules. CHARM Therapeutics Announces Collaboration with Bristol Myers Squibb to Enable and Accelerate Small Molecule Drug Discovery Programs. Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results. DeWinter MA.

Virus 52

Virus Engineering RNA Small Molecule 52

The Pharma Data

JANUARY 10, 2021

“We expect 2021 will mark a number of key clinical and commercial milestones. By the end of the year, we expect to have five independent TransCon product candidates in clinical development leveraging TransCon technologies through our algorithm for product innovation. . ?. ?. .

Clinical Trials 40

Clinical Trials Clinical Development Small Molecule Trials 40

The Pharma Data

JANUARY 18, 2021

SEMDEXA is a trademark of Semnur Pharmaceuticals, Inc. ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc. for the treatment of post-herpetic neuralgia. All other trademarks are the property of their respective owners. © 2021 Sorrento Therapeutics, Inc. All Rights Reserved. Source link.

Clinical Trials 40

Clinical Trials Small Molecule Trials Therapies 40

The Pharma Data

DECEMBER 15, 2020

Anokion is responsible for preclinical activities and Phase I clinical development of partnered programs, and Bristol Myers Squibb will fund subsequent trials and commercial activities at clinical proof-of-concept. Small Molecule Inhibitors. Oral, Small Molecules. Warm Autoimmune Hemolytic Anemia.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

The Pharma Data

DECEMBER 2, 2020

HZI – Germany’s Helmholtz Centre for Infection Research (HZI) secured two awards worth up to $15 million from CARB-X to develop non-traditional approaches against antibiotic-resistant pathogens. The goal is to develop a first-in-class treatment for Staphylococcus aureus infections and thereby prevent exacerbation of pneumonia.

Licensing 52

Licensing Licensing DNA Vaccine 52

The Pharma Data

JANUARY 17, 2021

“This result provides a foundation for a clinical development program using higher doses of setanaxib across a variety of orphan indications. Genkyotex’s discovery platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes. About Calliditas.

Trials 40

Trials Clinical Trials Pharmacokinetics Small Molecule 40

Agency IQ

JULY 26, 2024

Postapproval manufacturing changes for biological products During clinical development or following a product’s approval , sponsors and/or manufacturers may identify the need for a change in the product, production process, quality controls, equipment, facilities, responsible personnel, or labeling. Any CMC changes (e.g.,

Biosimilars 40

Biosimilars Science FDA Production 40

The Pharma Data

APRIL 27, 2021

Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. For more information, please visit www.BioNTech.de.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

SEPTEMBER 9, 2020

Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. For more information, please visit www.BioNTech.de.

Vaccine 52

Vaccine Clinical Trials Trials Government 52

The Pharma Data

SEPTEMBER 9, 2020

Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. For more information, please visit www.BioNTech.de.

Vaccine 52

Vaccine RNA Clinical Trials Trials 52

The Pharma Data

AUGUST 20, 2020

Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. For more information, please visit www.BioNTech.de.

Vaccine 52

Vaccine Clinical Trials Trials Immune Response 52

The Pharma Data

NOVEMBER 9, 2020

Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. For more information, please visit www.BioNTech.de.

Vaccine 40

Vaccine Clinical Trials Trials FDA 40

The Pharma Data

DECEMBER 12, 2020

12, 2020– AstraZeneca and Alexion Pharmaceuticals, Inc. AstraZeneca has developed a broad range of technologies, initially focused on small molecules and biologics and with a growing focus in precision medicine, genomics, oligonucleotides and epigenetics. Source: Alexion Pharmaceuticals, Inc. Source link.

Regulations 75

Regulations International Disease Small Molecule 75

Conversations in Drug Development Trends

MAY 30, 2024

Differences in regulatory sentiments and industry sponsors’ subsequent clinical development strategies historically restricted access based on geography. However, work is needed before CRISPR-mediated treatments become possible, including a better understanding of the genes involved in ALS.

Treatment 81

Treatment Clinical Trials Small Molecule Therapies 81